High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders

TY - JOUR

T1 - High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders

AU - Lam, J.U.H.

AU - Elfström, K M

AU - Ejegod, D. M.

AU - Pedersen, H.

AU - Rygaard, C.

AU - Rebolj, M.

AU - Lynge, E

AU - Juul, K. E.

AU - Kjær, S. K.

AU - Dillner, J.

AU - Bonde, J.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background:Self-sampling for human papillomavirus (HPV) offered to women who do not participate in cervical cancer screening is an increasingly popular method to increase screening coverage. The rationale behind self-sampling is that unscreened women harbour a high proportion of undetected precancer lesions. Here, we compare the cervical intraepithelial neoplasia grade 2 or worse (≥CIN2) detection rate between non-attenders who participated in self-sampling and women attending routine screening.Methods:A total of 23 632 women who were qualified as non-attenders in the Copenhagen Region were invited for HPV-based self-sampling. Of these, 4824 women returned a self-sample, and HPV-positive women were referred for cytology and HPV co-testing as follow-up. The entire cohort and a reference cohort (3347 routinely screened women) were followed for histopathology confirmed ≥CIN2. Odds ratio (OR) and the relative positive predictive value of ≥CIN2 detection between the two populations were estimated.Results:Women participating in self-sampling had a higher ≥CIN2 detection than women undergoing routine cytology-based screening (OR=1.83, 95% CI: 1.21-2.77) and a similar detection as routinely screened women tested with cytology and HPV testing (OR=1.03, 95% CI: 0.75-1.40). The positive predictive value for ≥CIN2 was higher in screening non-attenders than in routinely HPV- and cytology-screened screened women (36.5% vs 25.6%, respectively).Conclusions:Self-sampling offered to non-attenders showed higher detection rates for ≥CIN2 than routine cytology-based screening, and similar detection rates as HPV and cytology co-testing. This reinforces the importance of self-sampling for screening non-attenders in organised cervical cancer screening.

AB - Background:Self-sampling for human papillomavirus (HPV) offered to women who do not participate in cervical cancer screening is an increasingly popular method to increase screening coverage. The rationale behind self-sampling is that unscreened women harbour a high proportion of undetected precancer lesions. Here, we compare the cervical intraepithelial neoplasia grade 2 or worse (≥CIN2) detection rate between non-attenders who participated in self-sampling and women attending routine screening.Methods:A total of 23 632 women who were qualified as non-attenders in the Copenhagen Region were invited for HPV-based self-sampling. Of these, 4824 women returned a self-sample, and HPV-positive women were referred for cytology and HPV co-testing as follow-up. The entire cohort and a reference cohort (3347 routinely screened women) were followed for histopathology confirmed ≥CIN2. Odds ratio (OR) and the relative positive predictive value of ≥CIN2 detection between the two populations were estimated.Results:Women participating in self-sampling had a higher ≥CIN2 detection than women undergoing routine cytology-based screening (OR=1.83, 95% CI: 1.21-2.77) and a similar detection as routinely screened women tested with cytology and HPV testing (OR=1.03, 95% CI: 0.75-1.40). The positive predictive value for ≥CIN2 was higher in screening non-attenders than in routinely HPV- and cytology-screened screened women (36.5% vs 25.6%, respectively).Conclusions:Self-sampling offered to non-attenders showed higher detection rates for ≥CIN2 than routine cytology-based screening, and similar detection rates as HPV and cytology co-testing. This reinforces the importance of self-sampling for screening non-attenders in organised cervical cancer screening.

KW - Journal Article

U2 - 10.1038/bjc.2017.371

DO - 10.1038/bjc.2017.371

M3 - Journal article

C2 - 29136403

SN - 0007-0920

VL - 118

SP - 138

EP - 144

JO - The British journal of cancer. Supplement

JF - The British journal of cancer. Supplement

ER -